The government has unveiled its ambition for the NHS to become “the most advanced health system in the world” through use of the “best innovations in new technology and artificial intelligence”.
News
Gilead, Galapagos’ filgotinib succeeds in PhII ankylosing spondylitis trial
A mid-stage trial assessing Gilead and Galapagos’ JAK 1 inhibitor filgotinib in ankylosing spondylitis has hit its targets.
The PharmaTimes Marketer of the Year competition closes for entry next Friday – don’t miss this great opportunity!
Now in it’s 25th year, the PharmaTimes Marketer of the Year competition closes for entry on Friday 14th September – make sure you take advantage of this great opportunity for you and your team to compete, benchmark, learn and raise standards in pharma marketing.
FDA extends review time for Roche’s Tecentriq/Avastin combo
US regulators have extended the review period for Roche’s application to market Tecentriq in combination with Avastin, carboplatin and paclitaxel for first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC).
Teva drops development of laquinimod
Teva Pharmaceutical Industries has decided not to pursue development of laquinimod, and has returned rights to the drug back to Swedish group Active Biotech.
Celltrion calls for wider use of biologics in RA
Celltrion Healthcare is calling on the NHS to consider lowering the threshold for starting biologics in patients with rheumatoid arthritis (RA), and to put in place measures to boost patient access to such treatment.
New chair put forward for NHS England
Lord Prior of Brampton has been named as the government’s preferred new chair of NHS England, replacing Professor Sir Malcolm Grant.
Novartis to sell Sandoz assets to Aurobindo for $900m
Novartis is selling parts of its generics business Sandoz to Aurobindo in a deal worth at least $900 million.
PharmaTimes Sales Awards – entry deadline approaching
The inaugural PharmaTimes Sales Awards – established to recognise and celebrate the very best sales professionals in the industry today – will close for entries on September 7.
Priority review for MSD’s Keytruda for Merkel cell carcinoma
US regulators are undertaking a priority review of MSD’s Keytruda for the treatment of adult and paediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
Horizon completes enrollment in TED trial early
Horizon Pharma says it has completed enrollment in a confirmatory Phase III trial of teprotumumab in patients living with moderate-to-severe active thyroid eye disease (TED) ahead of schedule.
Study discovers immunotherapy could treat some aggressive prostate cancers
New research has discovered a subset of men with prostate cancer who have specific faults in their tumours that significantly worsen their chances of survival, but could mean they are more likely to benefit from immunotherapy.
NHS England strikes deal with Novartis on Kymriah
Hospitals are gearing up to offer Novartis’ ground-breaking CAR-T therapy Kymriah to children with advanced leukaemia, after the drugmaker reached a deal with NHS England over its provision.
NICE u-turn approves funding for rare disease therapy Crysvita
The National Institute for Health and Care Excellence (NICE) has changed its position on NHS funding for Kyowa Kirin International’s Crysvita, now endorsing the drug’s use to treat X-linked hypophosphataemia (XLH) in children and young people with growing bones in England and Wales.
80% at risk of early death because of an aged heart, warns PHE
Four in five people have a heart age older than their real age, leaving them at risk of early death from cardiovascular disease, Public Health England data show.
